FilingSEC EDGAR6-K
CytoMed Therapeutics Receives Nasdaq Minimum Bid Price Deficiency Notice
· SEC accepted
StageNotice Received
Filing content
CytoMed Therapeutics announced it received a notice from Nasdaq regarding non-compliance with the minimum bid price requirement and has until April 5, 2027, to regain compliance.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…